Maximilian Alexander Zierke, Christine Rangger, Kimia Samadikhah, Andreas Martin Schmid, Roland Haubner
{"title":"<sup>68</sup>Ga-Labeled Glycopeptides as Effective Tools for Liver Function Imaging.","authors":"Maximilian Alexander Zierke, Christine Rangger, Kimia Samadikhah, Andreas Martin Schmid, Roland Haubner","doi":"10.1021/acs.molpharmaceut.4c01453","DOIUrl":null,"url":null,"abstract":"<p><p>[<sup>99m</sup>Tc]Tc-GSA, an albumin-based glycoprotein, is routinely used in Japan to measure the asialoglycoprotein receptor (ASGR) density via single photon emission tomography. Here we describe the development of <sup>68</sup>Ga-labeled peptide-based alternatives. Peptides were assembled on a solid support using a fragment coupling strategy. Glycosylation was carried out via a click chemistry approach resulting in a set of three peptides with increasing amounts of d-galactose (<i>n</i> = 3, 6, and 9) as well as one glycopeptide bearing nine <i>N</i>-acetylgalactosamine residues. <sup>68</sup>Ga-labeling of all compounds could be achieved in high radiochemical yields (>95%). Radiotracers exhibited high hydrophilicity, good metabolic stability in human serum and protein binding between 12 and 22%. The IC<sub>50</sub> values improved in the series tri-, hexa-, and nonamer with an IC<sub>50</sub> of 50 ± 30 pM for the latter one. In analogy, the <i>in vivo</i> biodistribution studies revealed increased liver uptake in the series of [<sup>68</sup>Ga]Ga-<b>NODAGA-TriLysan</b> (9.4 ± 2.0% ID/g, 30 min p.i.), [<sup>68</sup>Ga]Ga-<b>NODAGA-HexaLysan</b> (55.5 ± 7.4% ID/g, 30 min p.i.), and [<sup>68</sup>Ga]Ga-<b>NODAGA-NonaLysan</b> (79.6 ± 8.0% ID/g, 30 min p.i.). [<sup>68</sup>Ga]Ga-NODAGA-GalNAc-NonaLysan reached comparable liver uptake to [<sup>68</sup>Ga]Ga-<b>NODAGA-NonaLysan</b>, but showed higher accumulation in nontarget organs. The impressive imaging properties of [<sup>68</sup>Ga]Ga-<b>NODAGA-NonaLysan</b> were also confirmed by the PET/MR imaging studies in mice. Hence, [<sup>68</sup>Ga]Ga-<b>NODAGA-NonaLysan</b> represents a new PET radiopharmaceutical with even better imaging properties than [<sup>99m</sup>Tc]Tc-GSA.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":" ","pages":""},"PeriodicalIF":4.5000,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Pharmaceutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acs.molpharmaceut.4c01453","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
[99mTc]Tc-GSA, an albumin-based glycoprotein, is routinely used in Japan to measure the asialoglycoprotein receptor (ASGR) density via single photon emission tomography. Here we describe the development of 68Ga-labeled peptide-based alternatives. Peptides were assembled on a solid support using a fragment coupling strategy. Glycosylation was carried out via a click chemistry approach resulting in a set of three peptides with increasing amounts of d-galactose (n = 3, 6, and 9) as well as one glycopeptide bearing nine N-acetylgalactosamine residues. 68Ga-labeling of all compounds could be achieved in high radiochemical yields (>95%). Radiotracers exhibited high hydrophilicity, good metabolic stability in human serum and protein binding between 12 and 22%. The IC50 values improved in the series tri-, hexa-, and nonamer with an IC50 of 50 ± 30 pM for the latter one. In analogy, the in vivo biodistribution studies revealed increased liver uptake in the series of [68Ga]Ga-NODAGA-TriLysan (9.4 ± 2.0% ID/g, 30 min p.i.), [68Ga]Ga-NODAGA-HexaLysan (55.5 ± 7.4% ID/g, 30 min p.i.), and [68Ga]Ga-NODAGA-NonaLysan (79.6 ± 8.0% ID/g, 30 min p.i.). [68Ga]Ga-NODAGA-GalNAc-NonaLysan reached comparable liver uptake to [68Ga]Ga-NODAGA-NonaLysan, but showed higher accumulation in nontarget organs. The impressive imaging properties of [68Ga]Ga-NODAGA-NonaLysan were also confirmed by the PET/MR imaging studies in mice. Hence, [68Ga]Ga-NODAGA-NonaLysan represents a new PET radiopharmaceutical with even better imaging properties than [99mTc]Tc-GSA.
期刊介绍:
Molecular Pharmaceutics publishes the results of original research that contributes significantly to the molecular mechanistic understanding of drug delivery and drug delivery systems. The journal encourages contributions describing research at the interface of drug discovery and drug development.
Scientific areas within the scope of the journal include physical and pharmaceutical chemistry, biochemistry and biophysics, molecular and cellular biology, and polymer and materials science as they relate to drug and drug delivery system efficacy. Mechanistic Drug Delivery and Drug Targeting research on modulating activity and efficacy of a drug or drug product is within the scope of Molecular Pharmaceutics. Theoretical and experimental peer-reviewed research articles, communications, reviews, and perspectives are welcomed.